- Home
- ATAI vs LUNG Comparison
ATAI vs LUNG Comparison
Compare ATAI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- LUNG
- Stock Information
- Founded
- ATAI 2018
- LUNG 1995
- Country
- ATAI Germany
- LUNG United States
- Employees
- ATAI N/A
- LUNG N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- LUNG Industrial Specialties
- Sector
- ATAI Health Care
- LUNG Health Care
- Exchange
- ATAI Nasdaq
- LUNG Nasdaq
- Market Cap
- ATAI 271.6M
- LUNG 299.3M
- IPO Year
- ATAI 2021
- LUNG 2020
- Fundamental
- Price
- ATAI $1.45
- LUNG $7.77
- Analyst Decision
- ATAI Strong Buy
- LUNG Strong Buy
- Analyst Count
- ATAI 4
- LUNG 7
- Target Price
- ATAI $9.00
- LUNG $12.64
- AVG Volume (30 Days)
- ATAI 2.1M
- LUNG 464.2K
- Earning Date
- ATAI 03-17-2025
- LUNG 04-30-2025
- Dividend Yield
- ATAI N/A
- LUNG N/A
- EPS Growth
- ATAI N/A
- LUNG N/A
- EPS
- ATAI N/A
- LUNG N/A
- Revenue
- ATAI $308,000.00
- LUNG $83,789,000.00
- Revenue This Year
- ATAI N/A
- LUNG $17.96
- Revenue Next Year
- ATAI $20.00
- LUNG $18.35
- P/E Ratio
- ATAI N/A
- LUNG N/A
- Revenue Growth
- ATAI N/A
- LUNG 22.01
- 52 Week Low
- ATAI $0.78
- LUNG $5.46
- 52 Week High
- ATAI $2.85
- LUNG $10.01
- Technical
- Relative Strength Index (RSI)
- ATAI 43.24
- LUNG 52.56
- Support Level
- ATAI $1.33
- LUNG $7.65
- Resistance Level
- ATAI $1.48
- LUNG $8.12
- Average True Range (ATR)
- ATAI 0.11
- LUNG 0.49
- MACD
- ATAI -0.01
- LUNG -0.06
- Stochastic Oscillator
- ATAI 43.41
- LUNG 45.71
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.